Phase 1Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1043 Following Single and Multiple Ascending Doses Via Subcutaneous and/or Intravenous Administration in Healthy Adult Participants Living With Overweight and/or Obesity.
- Sponsor
- AstraZeneca (Industry)
- Enrolment
- 104 planned
- Conditions
- Healthy Participants; Obesity
- Interventions
- AZD1043; Placebo
- Ages
- adults, older adults
- Registry
- NCT07511205
Full record on ClinicalTrials.gov
From the registry
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.
Primary outcomes
- Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs)
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started